Rescue Therapy
Cross-source consensus on Rescue Therapy from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Dosage & preparation
Comparisons
Evidence quality
Highlighted claims
- Starting at week 24, placebo participants with at least 50% regain of SURMOUNT-5 weight loss began rescue orforglipron. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Rescue dosing began at 1 mg orally once daily and escalated every four weeks to the maximum tolerated dose. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Other oral obesity medications were not allowed as rescue therapy. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Rescue therapy limited harms from weight regain but reduced the interpretability of placebo comparisons after week 24. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- The availability of rescue therapy appeared to prevent further average weight increases from week 24 to week 52. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial